Equities analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Rating) to report earnings per share of ($0.06) for the current quarter, Zacks reports. Two analysts have provided estimates for VistaGen Therapeutics’ earnings. VistaGen Therapeutics posted earnings per share of ($0.20) during the same quarter last year, which would suggest a positive year over year growth […]
Brokerages predict that VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Rating) will report sales of $330,000.00 for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for VistaGen Therapeutics’ earnings. The lowest sales estimate is $300,000.00 and the highest is $360,000.00. VistaGen Therapeutics reported sales of $440,000.00 in the same quarter last year, which […]
Analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Rating) to post earnings per share of ($0.06) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for VistaGen Therapeutics’ earnings. VistaGen Therapeutics reported earnings per share of ($0.20) during the same quarter last year, which suggests a positive year-over-year growth rate […]
Wall Street analysts forecast that VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Rating) will announce sales of $330,000.00 for the current quarter, Zacks reports. Two analysts have issued estimates for VistaGen Therapeutics’ earnings. The lowest sales estimate is $300,000.00 and the highest is $360,000.00. VistaGen Therapeutics reported sales of $440,000.00 during the same quarter last year, […]